Last updated 8 days ago

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

4300 patients around the world
Available in Colombia, United States, Mexico, Argentina, Brazil
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months. The eligible patients must have intermediate or high risk of recurrence, as defined by specified clinical and biologic criteria. Prior use of CDK4/6 inhibitors is permitted. The primary endpoint of the study is Invasive breast cancer-free survival (IBCFS) and main secondary endpoints include Invasive disease-free survival (IDFS), Distant relapse-free survival (DRFS), Overall survival (OS), Safety and Clinical Outcome Assessments (COAs). Patients will be followed for 10 years from randomization of the last patient.
AstraZeneca
14Research sites
4300Patients around the world

This study is for people with

Breast Cancer

Requirements for the patient

To 130 Years
All Gender

Medical requirements

Sites

Hospital Británico de Buenos Aires - CABA
Hospital Británico de Buenos Aires - CABA
Recruiting
Perdriel 74, CABA, Buenos Aires
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
25 de mayo 174, Viedma, Río Negro
Instituto de Investigaciones Clínicas Mar del Plata
Instituto de Investigaciones Clínicas Mar del Plata
Av. Colón 3456, Mar del Plata, Buenos Aires
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Laprida 532 Este, San Juan
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Recruiting
Av. Pueyrredon 1746, CABA, Buenos Aires
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Av. Crámer 1180, CABA, Buenos Aires
Centro Médico Caipo (centro para la atención integral de pacientes oncológicos)
Recruiting
Av Sarmiento 157, San Miguel de Tucumán
Hospital Alemán
Recruiting
Av. Pueyrredón 1640, CABA, Buenos Aires
Centro Médico San Roque S.R.L. - Tucumán
Recruiting
Balcarce 579, Tucumán
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Recruiting
Av. San Martín 5481, CABA, Buenos Aires
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy